JNJ Secures FDA Approval for IMAAVY to Treat Rare Blood Disorder

Johnson & Johnson (NYSE: JNJ) has secured U.S. Food and Drug Administration approval for its drug IMAAVY to treat warm autoimmune hemolytic anemia in patients 12 and older who are currently or were previously treated with corticosteroids.

The approval, which was the result of a Priority Review, marks the first FDA-approved therapy specifically for this rare, potentially life-threatening blood disorder. Warm autoimmune hemolytic anemia occurs when immunoglobulin G autoantibodies attach to and destroy red blood cells, causing severe anemia and fatigue in those affected.

IMAAVY is designed to target and reduce pathogenic IgG autoantibodies while preserving B-cell function. According to Johnson & Johnson, the drug's safety profile in a Phase 2/3 study was consistent with its established profile in generalized myasthenia gravis, and the most common adverse reactions were peripheral edema, diarrhea, and fever.

David Kuter, a physician at Massachusetts General Hospital and professor of medicine at Harvard Medical School, stated that 'The Phase 2/3 ENERGY study demonstrates that targeting pathogenic IgG can meaningfully change the treatment paradigm for wAIHA.' The approval expands Johnson & Johnson's use of IMAAVY beyond generalized myasthenia gravis.